Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.

Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Dos Santos C, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W.

Oncogene. 2018 Sep;37(39):5269-5280. doi: 10.1038/s41388-018-0288-y. Epub 2018 May 31.

2.

Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma.

Hijazi Y, Klinger M, Kratzer A, Wu B, Baeuerle PA, Kufer P, Wolf A, Nagorsen D, Zhu M.

Curr Clin Pharmacol. 2018;13(1):55-64. doi: 10.2174/1574884713666180518102514.

3.

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC.

Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22. Erratum in: Blood. 2019 Jun 13;133(24):2625.

4.

First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors.

Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, Rasmussen E, Amore BM, Nagorsen D, Hill JS, Stephenson J Jr.

Clin Cancer Res. 2017 Oct 1;23(19):5703-5710. doi: 10.1158/1078-0432.CCR-16-3261. Epub 2017 Jun 27.

5.

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS.

N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.

6.

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.

Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ.

Leukemia. 2017 Apr;31(4):777-787. doi: 10.1038/leu.2016.391. Epub 2016 Dec 28. Review.

PMID:
28028314
7.

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.

Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A, Rupertus K, Kanz L, Libicher M, Nagorsen D, Zugmaier G, Klinger M, Wolf A, Dorsch B, Quednau BD, Schmidt M, Scheele J, Baeuerle PA, Leo E, Bargou RC.

J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16.

PMID:
26884582
8.

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.

Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J, Zhang A, Nagorsen D, Bargou RC.

Blood. 2016 Mar 17;127(11):1410-6. doi: 10.1182/blood-2015-06-651380. Epub 2016 Jan 11.

9.

Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.

Stieglmaier J, Benjamin J, Nagorsen D.

Expert Opin Biol Ther. 2015;15(8):1093-9. doi: 10.1517/14712598.2015.1041373. Epub 2015 May 13. Review.

PMID:
25971805
10.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Topp MS, Gökbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foà R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Brüggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM.

Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16. Erratum in: Lancet Oncol. 2015 Apr;16(4):e158.

PMID:
25524800
11.

A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy.

Golay J, D'Amico A, Borleri G, Bonzi M, Valgardsdottir R, Alzani R, Cribioli S, Albanese C, Pesenti E, Finazzi MC, Quaresmini G, Nagorsen D, Introna M, Rambaldi A.

J Immunol. 2014 Nov 1;193(9):4739-47. doi: 10.4049/jimmunol.1401550. Epub 2014 Sep 29.

12.

Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy.

Zimmerman Z, Maniar T, Nagorsen D.

Int Immunol. 2015 Jan;27(1):31-7. doi: 10.1093/intimm/dxu089. Epub 2014 Sep 19. Review.

PMID:
25239133
13.

Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells.

Wong R, Pepper C, Brennan P, Nagorsen D, Man S, Fegan C.

Haematologica. 2013 Dec;98(12):1930-8. doi: 10.3324/haematol.2012.082248. Epub 2013 Jun 28.

14.

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.

Topp MS, Gökbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A, Stelljes M, Schaich M, Köhne-Volland R, Brüggemann M, Ottmann OG, Burmeister T, Baeuerle PA, Nagorsen D, Schmidt M, Einsele H, Riethmüller G, Kneba M, Hoelzer D, Kufer P, Bargou RC.

Blood. 2012 Dec 20;120(26):5185-7. doi: 10.1182/blood-2012-07-441030. Epub 2012 Sep 28.

PMID:
23024237
15.

Blinatumomab: a historical perspective.

Nagorsen D, Kufer P, Baeuerle PA, Bargou R.

Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Review.

PMID:
22940266
16.

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, Stelljes M, Brüggemann M, Hoelzer D, Degenhard E, Nagorsen D, Baeuerle PA, Wolf A, Kufer P.

Blood. 2012 Jun 28;119(26):6226-33. doi: 10.1182/blood-2012-01-400515. Epub 2012 May 16.

PMID:
22592608
17.

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, Stelljes M, Schaich M, Degenhard E, Köhne-Volland R, Brüggemann M, Ottmann O, Pfeifer H, Burmeister T, Nagorsen D, Schmidt M, Lutterbuese R, Reinhardt C, Baeuerle PA, Kneba M, Einsele H, Riethmüller G, Hoelzer D, Zugmaier G, Bargou RC.

J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.

PMID:
21576633
18.

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.

Nagorsen D, Baeuerle PA.

Exp Cell Res. 2011 May 15;317(9):1255-60. doi: 10.1016/j.yexcr.2011.03.010. Epub 2011 Mar 16. Review.

PMID:
21419116
19.

Comparison of T-cell receptor repertoire restriction in blood and tumor tissue of colorectal cancer patients.

Ochsenreither S, Fusi A, Wojtke S, Busse A, Nüssler NC, Thiel E, Keilholz U, Nagorsen D.

J Transl Med. 2010 Apr 12;8:35. doi: 10.1186/1479-5876-8-35.

20.

Regulatory (FOXP3+) T cells as target for immune therapy of cervical intraepithelial neoplasia and cervical cancer.

Loddenkemper C, Hoffmann C, Stanke J, Nagorsen D, Baron U, Olek S, Huehn J, Ritz JP, Stein H, Kaufmann AM, Schneider A, Cichon G.

Cancer Sci. 2009 Jun;100(6):1112-7.

21.

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.

Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G.

Leuk Lymphoma. 2009 Jun;50(6):886-91. doi: 10.1080/10428190902943077. Review.

PMID:
19455460
22.

Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure.

Westermann D, Riad A, Richter U, Jäger S, Savvatis K, Schuchardt M, Bergmann N, Tölle M, Nagorsen D, Gotthardt M, Schultheiss HP, Tschöpe C.

Basic Res Cardiol. 2009 Sep;104(5):499-509. doi: 10.1007/s00395-009-0014-6. Epub 2009 Mar 3.

PMID:
19255799
23.

Antiviral cellular immunity in colorectal cancer patients.

Kiewe P, Wojtke S, Thiel E, Nagorsen D.

Hum Immunol. 2009 Feb;70(2):85-8. doi: 10.1016/j.humimm.2008.12.004. Epub 2009 Jan 6.

PMID:
19133306
24.

Relative quantification of TCR Vbeta-chain families by real time PCR for identification of clonal T-cell populations.

Ochsenreither S, Fusi A, Busse A, Nagorsen D, Schrama D, Becker J, Thiel E, Keilholz U.

J Transl Med. 2008 Jul 1;6:34. doi: 10.1186/1479-5876-6-34.

25.

Combined automated cell and flow cytometric analysis enables recognition of persistent polyclonal B-cell lymphocytosis (PPBL), a study of 25 patients.

Schmidt-Hieber M, Burmeister T, Weimann A, Nagorsen D, Hofmann WK, Thiel E, Schwartz S.

Ann Hematol. 2008 Oct;87(10):829-36. doi: 10.1007/s00277-008-0529-1. Epub 2008 Jun 28.

PMID:
18587574
26.

Foxp3 and microsatellite stability phenotype in colorectal cancer.

Loddenkemper C, Nagorsen D, Zeitz M.

Gut. 2008 Jun;57(6):725-6. doi: 10.1136/gut.2007.139568. Review. No abstract available.

PMID:
18477674
27.

HLA-A2 expression, stage, and survival in colorectal cancer.

Kiewe P, Mansmann V, Scheibenbogen C, Buhr HJ, Thiel E, Nagorsen D.

Int J Colorectal Dis. 2008 Aug;23(8):767-72. doi: 10.1007/s00384-008-0488-y. Epub 2008 May 7.

PMID:
18461337
28.

HLA typing demands for peptide-based anti-cancer vaccine.

Nagorsen D, Thiel E.

Cancer Immunol Immunother. 2008 Dec;57(12):1903-10. doi: 10.1007/s00262-008-0493-6. Epub 2008 Mar 4.

PMID:
18317754
29.

Monoclonal antibodies in clinical hematology and oncology.

Nagorsen D, Thiel E.

Curr Opin Investig Drugs. 2007 Dec;8(12):996-1001. Review.

PMID:
18058570
31.

In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer.

Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D.

J Transl Med. 2006 Dec 13;4:52.

32.

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma.

Kiewe P, Bechrakis NE, Schmittel A, Ruf P, Lindhofer H, Thiel E, Nagorsen D.

Ann Oncol. 2006 Dec;17(12):1830-4. Epub 2006 Sep 13.

PMID:
16971663
33.

Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells.

Na IK, Keilholz U, Letsch A, Bauer S, Asemissen AM, Nagorsen D, Thiel E, Scheibenbogen C.

Cancer Immunol Immunother. 2007 Mar;56(3):391-6. Epub 2006 Jul 19.

PMID:
16850346
34.
35.

Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytes.

Lim JB, Provenzano M, Kwon OH, Bettinotti M, Caruccio L, Nagorsen D, Stroncek D.

Exp Hematol. 2006 Mar;34(3):296-307.

PMID:
16543064
36.

Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms.

Stroncek DF, Basil C, Nagorsen D, Deola S, Aricó E, Smith K, Wang E, Marincola FM, Panelli MC.

J Transl Med. 2005 Jun 13;3:24.

37.

Polarized monocyte response to cytokine stimulation.

Nagorsen D, Deola S, Smith K, Wang E, Monsurro V, Zanovello P, Marincola FM, Panelli MC.

Genome Biol. 2005;6(2):R15. Epub 2005 Jan 21.

38.

T cell responses against tumor associated antigens and prognosis in colorectal cancer patients.

Nagorsen D, Scheibenbogen C, Letsch A, Germer CT, Buhr HJ, Hegewisch-Becker S, Rivoltini L, Thiel E, Keilholz U.

J Transl Med. 2005 Jan 19;3(1):3.

39.

Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients.

Letsch A, Keilholz U, Fluck M, Nagorsen D, Asemissen AM, Schmittel A, Thiel E, Scheibenbogen C.

Int J Cancer. 2005 May 10;114(6):936-41.

40.

Degree of CD14 expression in melanoma infiltrating mononuclear phagocytes.

Nagorsen D, Fetsch PA, Abati A, Marincola FM, Panelli MC.

J Dermatol Sci. 2005 Jan;37(1):52-4. Epub 2004 Dec 8. No abstract available.

PMID:
15619435
41.

Immunological monitoring of cancer vaccine therapy.

Nagorsen D, Scheibenbogen C, Thiel E, Keilholz U.

Expert Opin Biol Ther. 2004 Oct;4(10):1677-84. Review.

PMID:
15461579
42.

A genomic- and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization.

Panelli MC, Martin B, Nagorsen D, Wang E, Smith K, Monsurro V, Marincola FM.

Cells Tissues Organs. 2004;177(3):124-31.

PMID:
15388986
43.

Selection and validation of endogenous reference genes using a high throughput approach.

Jin P, Zhao Y, Ngalame Y, Panelli MC, Nagorsen D, Monsurró V, Smith K, Hu N, Su H, Taylor PR, Marincola FM, Wang E.

BMC Genomics. 2004 Aug 13;5(1):55.

44.

Mechanism of immune response during immunotherapy.

Panelli MC, Nagorsen D, Wang E, Monsurro V, Jin P, Katia Z, Smith K, Ngalame Y, Marincola FM.

Yonsei Med J. 2004 Jun 30;45 Suppl:15-7.

45.

Quiescent phenotype of tumor-specific CD8+ T cells following immunization.

Monsurrò V, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K, Nagorsen D, Connors M, Jacobson S, Marincola FM.

Blood. 2004 Oct 1;104(7):1970-8. Epub 2004 Jun 8.

PMID:
15187028
46.

Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M.

Nagorsen D, Servis C, Lévy N, Provenzano M, Dudley ME, Marincola FM, Lévy F.

Cancer Immunol Immunother. 2004 Sep;53(9):817-24. Epub 2004 May 5.

PMID:
15133631
47.

Active-specific immunization against melanoma: is the problem at the receiving end?

Monsurrò V, Wang E, Panelli MC, Nagorsen D, Jin P, Katia Z, Smith K, Ngalame Y, Even J, Marincola FM.

Semin Cancer Biol. 2003 Dec;13(6):473-80. Review.

PMID:
15001166
48.

Cytokine and chemokine expression profiles of maturing dendritic cells using multiprotein platform arrays.

Nagorsen D, Marincola FM, Panelli MC.

Cytokine. 2004 Jan 7;25(1):31-5.

PMID:
14687583
49.

Ex vivo screening for immunodominant viral epitopes by quantitative real time polymerase chain reaction (qRT-PCR).

Provenzano M, Mocellin S, Bonginelli P, Nagorsen D, Kwon SW, Stroncek D.

J Transl Med. 2003 Dec 15;1(1):12.

50.

Natural T cell immunity against cancer.

Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U.

Clin Cancer Res. 2003 Oct 1;9(12):4296-303. Review.

Supplemental Content

Loading ...
Support Center